- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04619095
Reducing Pain and Anxiety Through Dietary Fiber Supplementation in Children With Abdominal Pain
Randomised, Blinded, Parallel, Placebo-controlled Study to Evaluate Whether Supplementation of the Dietary Fiber Psyllium Can Reduce Abdominal Pain and Improve Quality of Life and Anxiety in Children With Abdominal Pain.
Background - Mental health and pain problems in early childhood are major risk factors for serious mental health problems into adulthood. These long-term effects point toward the essential need for prevention and early intervention to curbing the rising tide of global mental health disease. New approaches to child and adolescent mental health are urgently needed.
This study focus on children with functional abdominal pain (FAP), which is defined as recurrent abdominal pain independent of bowel movements without an underlying medical cause. This population has a high co-occurrence of anxiety and somatic complaints. The effects of fiber on gastrointestinal pain have not yet been tested in this group. The investigators propose that supplementation with dietary fiber (psyllium) in children with FAP will promote SCFA production by the gut microbiota, reducing abdominal pain and subsequently anxiety and improving quality of life. Psyllium promotes SCFA production, is considered safe, and meta-analyses have identified it as the most potent fiber for reducing abdominal complaints in IBS patients, indicating strong potential for reducing abdominal pain in children with FAP.
It is essential that potential mechanisms through which psyllium-induced SCFA production can reduce abdominal pain and anxiety symptoms and improve quality of life are explored. This study will explore 3 mechanisms: 1) activation of the vagus nerve, as SCFAs can induce vagal signalling, and evidence suggests that vagus nerve stimulation can reduce pain and anxiety symptoms; 2) reduction in HPA-axis responsiveness, since fiber has been shown to do so in adults, and both abdominal pain and anxiety disorders are associated with increased HPA-axis activity; and 3) structural and functional brain changes in the amygdala and hippocampus, as SCFA can influence neuronal activity of specific brain regions and probiotics-induced improvements in mental health have been related to these brain regions in adults with IBS.
Research question & Objectives - The first objective is to provide a dietary fiber psyllium supplement to children (ages 8-16 years) who suffer from FAP. The aims are to: 1) determine whether psyllium reduces abdominal pain, 2) investigate whether this subsequently decreases anxiety and improves quality of life, and 3) assess associated gut-brain axis mediators, specifically the vagus nerve, HPA-axis, and brain networks.
Methods - The investigators propose a 12-week placebo-controlled double-blind parallel-group intervention pilot study (n=20/group) where children suffering from FAP will receive a daily supplement of either psyllium or placebo (maltodextrin). For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks. For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks. An initial lower dose was chosen to allow the gastrointestinal tract to acclimatize to the increase in dietary fiber. The dosages were chosen based on the fact that this age group typically consumes 10g less dietary fiber than recommended. All study measures are collected prior to, and after the intervention. The primary measure is abdominal pain frequency and intensity during 7 consecutive days. Secondary measures include parent and child reported anxiety and quality of life. Stool samples are used to determine gut microbiota and SCFAs. MRI will be used to assess the role of brain regions implicated in pain and anxiety. Respiratory sinus arrhythmia during seated rest will be used to assess basal vagal tone.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Pediatric GI Motility Laboratory at Alberta Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of functional abdominal pain as defined by the Rome IV criteria for childhood functional gastrointestinal disorders
Exclusion Criteria:
- Diagnosis of inflammatory bowel disease or irritable bowel syndrome
- Lactose intolerance
- Abdominal surgery within the past year
- Contraindications for imaging
- Antibiotic use over the last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psyllium
For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks.
For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
|
See the information already included in the arm descriptions.
|
Placebo Comparator: Placebo
For participants aged 8-11 and weighing > 24 kgs, the dosage is daily 3 grams for 2 weeks followed by daily 6 grams for 10 weeks.
For children aged 12-16 and weighing > 40 kgs, the dosage is daily 5 grams for 2 weeks followed by daily 10 grams for 10 weeks.
|
See the information already included in the arm descriptions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in abdominal pain scores as measured by an abdominal pain diary
Time Frame: Significant change from week-zero to week 12 between the active and placebo group
|
The score minimum on the scale is 0, the maximum is 20. Higher scores indicate a worse outcome. The abdominal pain score diary is adapted from: See et al., 2001 - DOI: 10.1023/a:1010793408132 |
Significant change from week-zero to week 12 between the active and placebo group
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Anxiety scores as measured by PROMIS Anxiety scale
Time Frame: Significant change from week-zero to week 12 between the active and placebo group
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) questionaire will be used.
The score minimum on the scale is 8, the maximum is 40.
Higher scores indicate a worse outcome.
|
Significant change from week-zero to week 12 between the active and placebo group
|
Quality of life as measured using the functional disability inventory (FDI)
Time Frame: Significant change from week-zero to week 12 between the active and placebo group
|
The functional disability inventory (FDI) questionnaire will be used.
The score minimum on the scale is 0, the maximum is 96.
Higher scores indicate a worse outcome.
|
Significant change from week-zero to week 12 between the active and placebo group
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool microbiome - Stool samples will be assayed using metagenome shotgun sequencing, after which alpha diversity is assessed.
Time Frame: Significant change in alpha diversity from week-zero to week 12 between the active and placebo group
|
Alpha diversity will be assessed using the Shannon diversity index.
|
Significant change in alpha diversity from week-zero to week 12 between the active and placebo group
|
Stool metabolome - Stool samples will be assayed using liquid chromatography-mass spectrometry for short-chain fatty acid levels
Time Frame: Significant change in short-chain fatty acid levels from week-zero to week 12 between the active and placebo group
|
Short-chain fatty acid levels are expressed as mM.
|
Significant change in short-chain fatty acid levels from week-zero to week 12 between the active and placebo group
|
Respiratory sinus arrhythmia.This will be quantified using the high-frequency component of heart-rate variability.
Time Frame: Significant change from week-zero to week 12 between the active and placebo group
|
Vagus nerve activity will be measured indirectly using respiratory sinus arrhythmia.
|
Significant change from week-zero to week 12 between the active and placebo group
|
Both structural and functional MRI will be used to quantify changes in connectivity between the amygdala and prefrontal cortex.
Time Frame: Significant change in amygdala-prefrontal cortex connectivity from week-zero to week 12 between the active and placebo group
|
Connectivity will be expressed as a z-score.
|
Significant change in amygdala-prefrontal cortex connectivity from week-zero to week 12 between the active and placebo group
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Gerald Giesbrecht, PhD, Depts. of Paediatrics and Community Health Sciences, University of Calgary
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB20-1373
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Abdominal Pain Syndrome
-
Baylor College of MedicineUniversity of WashingtonRecruitingIrritable Bowel Syndrome | Functional Abdominal Pain | Functional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Functional Bowel Disorder | Functional Abdominal Pain DisordersUnited States
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedFunctional Gastrointestinal Disorders | Functional Abdominal Pain Syndrome | Abdominal Pain (AP)
-
Michigan State UniversitySpectrum Health HospitalsWithdrawnFunctional Abdominal Pain SyndromeUnited States
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeNetherlands
-
Aarhus University HospitalKarolinska InstitutetRecruitingIrritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeDenmark
-
Medical College of WisconsinCompletedDyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders | Functional Abdominal Pain SyndromeUnited States
-
University Hospital TuebingenSymbioPharm GmbHUnknownIrritable Bowel Syndrome | Functional Abdominal Pain SyndromeGermany
-
Karolinska InstitutetChild and Adolescent Psychiatry, StockholmRecruitingFunctional Abdominal Pain SyndromeSweden
-
University of Warmia and MazuryNational Science Centre, PolandCompletedFunctional Abdominal Pain SyndromePoland
-
Assiut UniversityUnknownFunctional Abdominal Pain Syndrome
Clinical Trials on Psyllium
-
Unity Health TorontoUnknownHypercholesterolemia | Cardiovascular Risk Factor
-
University of UtahCompletedKidney DiseaseUnited States
-
Procter and GambleCompleted
-
Hungkuang UniversityNot yet recruitingSchizophrenia | Constipation | PsylliumTaiwan
-
Nutrabiotix, LLCRush University Medical CenterTerminatedConstipation-predominant IBS (IBS-C)United States
-
Francesco GabrielliCompletedConstipation | IncontinenceItaly
-
Procter and GambleDuke UniversityCompletedImpaired Fasting GlucoseUnited States
-
University of NottinghamIronwood Pharmaceuticals, Inc.Completed
-
Procter and GambleCompleted
-
US Department of Veterans AffairsCompletedFecal IncontinenceUnited States